Department of Otorhinolaryngology, Head & Neck Surgery and Audiology Rigshospitalet, University of Copenhagen
Copenhagen, 2100, Denmark
NCT Number: NCT03160495
The purpose of this study is to investigate if heterogeneity in head and neck squamous cell carcinoma as seen in functional imaging with PET/MR can be correlated to biologic heterogeneity in surgical specimens.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Copenhagen, 2100, Denmark
The following is a presentation of a prospective protocol, named FIGHHT, including patients with squamous cell carcinoma of the head and neck (HNSCC) who are referred for surgery.
This is a prospective imaging/biomarker expression study where patients referred for surgery for HNSCC will be included. The purpose of the study is to investigate if heterogeneity in HNSCC as seen in functional imaging with PET/MR can be correlated to biologic heterogeneity in surgical specimens.
Multiparametric imaging(MPI) is performed before surgery using a PET/MR system (Siemens Biograph mMR) with a 3 T magnet using a head and neck coil. The scan protocol includes diffusion weighted MRI, dynamic contrast enhanced perfusion MRI and FDG-PET (4 MBq/kg). Morphometric imaging is performed with a 3D T2 weighted sequence (SPACE, voxel size 1.0 mm isotropic in vivo and 0.5 mm isotropic for specimens).
The scans are evaluated by a radiologist and a specialist in nuclear medicine and regions of interest and reference areas (anatomical landmarks) are marked. The tumor and if indicated lymp nodes are removed en bloc and per-operatively the reference areas and other anatomical landmarks are marked in the specimen with intravenous tubes. The specimen is fixed to a corkboard and scanned morphometric (as described) using a knee coil before and after formalin fixation within 1 hour after surgery. The whole surgical specimen is sectioned for histological processing.
Tissue blocks will undergo microscopic pathological evaluation and IHC staining. The specific selection of cancer related IHC biomarkers is based on their relationship with tumor cell metabolism, radiotherapy resistance (proliferation and hypoxia), association with FDG accumulation and institutional experience from a previous study.
The quantified measurements from the FDG PET, DWI and DCE scan will be correlated to the expression of IHC biomarkers.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All patients are scanned with PET/MR prior to surgery.
Time frame: 3-6 months
Correlation between FDG uptake (measured as SUV) and expression of IHC biomarkers
Time frame: 3-6 months
Correlation between diffusion weighted imaging and expression of IHC biomarkers
Time frame: 3-6 months
Correlation between dynamic contrast enhancement and expression of IHC biomarkers
Rigshospitalet, Denmark
Other
Acronym: FIGHHT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01612351
Carcinoma, Carcinoma, Squamous Cell
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05482880
Behavior, Carcinoma
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT03381183
Carcinoma, Carcinoma, Squamous Cell
Tampa, Florida, United States
View Trial DetailsNCT03944915
Carcinoma, Carcinoma, Squamous Cell
Chicago, Illinois, United States
View Trial Details